VANCOUVER and SAN DIEGO, Dec. 13 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, reports financial results for the three and six months ended October 31, 2006 and an update on its programs.
